Economic cost of congenital CMV in the UK

Jenny Retzler, Nick Hex, Chris Bartlett, Anne Webb, Sharon Wood, Caroline Star, Paul Griffiths, Christine Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK. Design: The study collated available secondary data to develop a static cost model. Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016. Patients: Individuals of all ages with cCMV. Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae. Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV. Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.

Original languageEnglish
JournalArchives of Disease in Childhood
Early online date24 Nov 2018
DOIs
Publication statusPublished - 2018

Fingerprint

Cytomegalovirus
Economics
Costs and Cost Analysis
Public Sector
Viruses
Sensorineural Hearing Loss
Vaccines
Outcome Assessment (Health Care)

Cite this

Retzler, Jenny ; Hex, Nick ; Bartlett, Chris ; Webb, Anne ; Wood, Sharon ; Star, Caroline ; Griffiths, Paul ; Jones, Christine. / Economic cost of congenital CMV in the UK. In: Archives of Disease in Childhood. 2018.
@article{ac2f266f3ada4a5f82de45425913a59a,
title = "Economic cost of congenital CMV in the UK",
abstract = "Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK. Design: The study collated available secondary data to develop a static cost model. Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016. Patients: Individuals of all ages with cCMV. Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae. Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40{\%} of the costs were directly incurred by the public sector, with the remaining 60{\%} being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV. Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.",
keywords = "congenital abnorm, deafness, health economics, infectious diseases, neurodevelopment",
author = "Jenny Retzler and Nick Hex and Chris Bartlett and Anne Webb and Sharon Wood and Caroline Star and Paul Griffiths and Christine Jones",
year = "2018",
doi = "10.1136/archdischild-2018-316010",
language = "English",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",

}

Economic cost of congenital CMV in the UK. / Retzler, Jenny; Hex, Nick; Bartlett, Chris; Webb, Anne; Wood, Sharon; Star, Caroline; Griffiths, Paul; Jones, Christine.

In: Archives of Disease in Childhood, 2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Economic cost of congenital CMV in the UK

AU - Retzler, Jenny

AU - Hex, Nick

AU - Bartlett, Chris

AU - Webb, Anne

AU - Wood, Sharon

AU - Star, Caroline

AU - Griffiths, Paul

AU - Jones, Christine

PY - 2018

Y1 - 2018

N2 - Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK. Design: The study collated available secondary data to develop a static cost model. Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016. Patients: Individuals of all ages with cCMV. Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae. Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV. Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.

AB - Objective: Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK. Design: The study collated available secondary data to develop a static cost model. Setting: The model aimed to estimate costs of cCMV in the UK for the year 2016. Patients: Individuals of all ages with cCMV. Main outcome measures: Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae. Results: The model estimated that the total cost of cCMV to the UK in 2016 was £732 million (lower and upper estimates were between £495 and £942 million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV. Conclusions: The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.

KW - congenital abnorm

KW - deafness

KW - health economics

KW - infectious diseases

KW - neurodevelopment

UR - http://www.scopus.com/inward/record.url?scp=85057220529&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/economic-cost-congenital-cmv-uk

U2 - 10.1136/archdischild-2018-316010

DO - 10.1136/archdischild-2018-316010

M3 - Article

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

ER -